Two mostly vacant office buildings in Montgomery County lost the majority of their value in a foreclosure sale.

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target following ...

BTIG analysts have downgraded Globus Medical from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

Zimmer Biomet named Kevin Thornal as group president for global business and the Americas, according to a May 27 news release. Mr. Thornal will join the company July 1. He was previously CEO and ...

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high ...

Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or ...

Globus Medical seems to be reverting to form, reporting a big jump in operating profit and profit margin for Q1, 2025. Here ...

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with ...

From new partnerships and launches, here are six developments from Globus Medical so far in 2025. 1. OsteoCentric Technologies entered into a non-exclusive licensing agreement with Globus Medical.

The United States market has experienced a positive trend, rising 2.9% over the last week and 12% over the past year, with earnings projected to grow by 14% annually in the coming years. In this ...